Presentation is loading. Please wait.

Presentation is loading. Please wait.

A Acquire ovarian cancer cell lines from various repository ATCC (6), CRT (2), DSMZ (2), ECACC (7), Kyoto U (24), RIKEN (1) Cell line expansion & banking.

Published byEmery Curtis Modified over 8 years ago

Similar presentations

Presentation on theme: "A Acquire ovarian cancer cell lines from various repository ATCC (6), CRT (2), DSMZ (2), ECACC (7), Kyoto U (24), RIKEN (1) Cell line expansion & banking."— Presentation transcript:

1 A Acquire ovarian cancer cell lines from various repository ATCC (6), CRT (2), DSMZ (2), ECACC (7), Kyoto U (24), RIKEN (1) Cell line expansion & banking SGOCL (43) Downstream Analysis Immunofluorescence Staining DNA, RNA, Protein Extraction B RNA Gene Expression Profiling Phenotype-specific Gene Signatures EMT RT 2 Profiler qPCR Array Phenotype-specific Gene Expression Affymetrix GeneChip Human Gene 1.0 ST Array QA Agilent Bioanalyzer Parametric / Nonparametric Analysis Cell Functional Assays Migration Assay Invasion Assay Anoikis Assay Colony Assay Endpoint Readout Image Analysis Establish EM Phenotypic Characterisation Validate EMT Marker Expression Create EMT Spectrum Functional Correlation Supplementary Figure 1

2 Supplementary Figure 2

3 Supplementary Figure 3 A Caov3OVCAR-3PEO1OVCAR8 OVCA433IGROV1PEO4OVCA429 CH1SKOV3DOV13Hey C2 A2780Hey A8A1847TykNu B Caov3 IGROV1OVCA433OVCA429 CH1DOV13SKOV3Hey C2 A1847 PEO1OVCAR3OVCAR8 A2780Hey A8TykNu MigrationInvasion C D E OVCA433 HeyC2 Epithelial Intermediate E Intermediate M Mesenchymal Invasive Front F SKOV3 subcutaneous tumours Day 59 SKOV3 subcutaneous tumour. Measurements in centimeters (cm)

4 Control100 nM 5  M AZD0530 OVCAR3 (E) 500 nM AZD0530 OVCA433 (Int E) AZD0530 SKOV3 (Int M) AZD0530 OVCAR10 (M) Supplementary Figure 4

5 Supplementary Figure 5 A B

6 Supplementary Figure 6 A B

7 Supplementary Figure 7 1-yr PFS2-yr PFS 3-yr PFS4-yr PFSA B Phenotype Comparison Progression-free Survival (PFS) p-value (Log-rank) 1-yr2-yr3-yr4-yr E vs IE0.0790.6910.76250.4864 E vs IM0.210.1630.18220.2253 E vs M0.00140.00020.00240.007 IE vs IM0.96360.32890.15440.1043 IE vs M0.15380.00360.00530.0041 IM vs M0.29780.22090.42820.5109 C Phenotype Comparison Difference in RMST (95% CI) 12 month24 month36 month48 month E vs IE0.468 (0.346 - 0.589)0.979 (0.813 - 1.145)0.034 (-0.125 - 0.192)-1.96 (-2.101 - -1.819) E vs IM0.487 (0.370 - 0.604)2.311 (2.121 - 2.501)3.362 (3.18 - 3.544)4.173 (4.007 - 4.338) E vs M1.011 (0.875 - 1.147)4.155 (3.95 - 4.36)5.919 (5.731 - 6.106)6.542 (6.378 - 6.705) IE vs IM0.019 (-0.129 - 0.167)1.332 (1.141 - 1.524)3.328 (3.159 - 3.497)6.133 (5.987 - 6.278) IE vs M0.543 (0.376 - 0.71)3.176 (2.969 - 3.382)5.885 (5.711 - 6.059)8.502 (8.358 - 8.645) IM vs M0.524 (0.362 - 0.686)1.844 (1.614 - 2.074)2.557 (2.359 - 2.754)2.369 (2.201 - 2.537)

8 Supplementary Figure 8 E-cad/DAPI N-Cad/DAPI

Download ppt "A Acquire ovarian cancer cell lines from various repository ATCC (6), CRT (2), DSMZ (2), ECACC (7), Kyoto U (24), RIKEN (1) Cell line expansion & banking."

Similar presentations

AB C Breast cancer Gas6 RNA Seq D E F Figure S1. AXL and GAS6 expression correlates with a mesenchymal signature. (A) Scatter plot representing the RNA.

AB C Breast cancer Gas6 RNA Seq D E F Figure S1. AXL and GAS6 expression correlates with a mesenchymal signature. (A) Scatter plot representing the RNA.
Lung Cancer: What’s New and What’s Old? Presented By Leora Horn at 2014 ASCO Annual Meeting.

Lung Cancer: What’s New and What’s Old? Presented By Leora Horn at 2014 ASCO Annual Meeting.
MiRNA-drug resistance mechanisms Summary Hypothesis: The interplay between miRNAs, signaling pathways and epigenetic and genetic alterations are responsible.

MiRNA-drug resistance mechanisms Summary Hypothesis: The interplay between miRNAs, signaling pathways and epigenetic and genetic alterations are responsible.
Introduction Materials and Methods Results Conclusions CD133 Polymorphisms are associated with clinical outcome in metastatic colorectal cancer (mCRC)

Introduction Materials and Methods Results Conclusions CD133 Polymorphisms are associated with clinical outcome in metastatic colorectal cancer (mCRC)
CISC667, F05, Lec24, Liao1 CISC 667 Intro to Bioinformatics (Fall 2005) DNA Microarray, 2d gel, MSMS, yeast 2-hybrid.

CISC667, F05, Lec24, Liao1 CISC 667 Intro to Bioinformatics (Fall 2005) DNA Microarray, 2d gel, MSMS, yeast 2-hybrid.
Evaluating cell lines as tumor models by comparison of genomic profiles Domcke, S. et al. Nat. Commun 4:2126.

Evaluating cell lines as tumor models by comparison of genomic profiles Domcke, S. et al. Nat. Commun 4:2126.
Suppl. Figure 1 A B Suppl. Figure 1. Relative (A) miR-21 and (B) miR-224 expression levels in HCC tumors in different stages (I,II,III,IV) assessed by.

Suppl. Figure 1 A B Suppl. Figure 1. Relative (A) miR-21 and (B) miR-224 expression levels in HCC tumors in different stages (I,II,III,IV) assessed by.
November 2009.  Implemented in GMSR, summer 2009  Probe feature size 11um; mini array format  4 identical probes per miRNA (also probes for snoRNAs)

November  Implemented in GMSR, summer 2009  Probe feature size 11um; mini array format  4 identical probes per miRNA (also probes for snoRNAs)
Molecular classification of renal cell carcinoma subtypes using microRNA signatures Zaravinos A 1, Lambrou GI 2, Mourmouras N 3, Delakas D 3, Deltas C.

Molecular classification of renal cell carcinoma subtypes using microRNA signatures Zaravinos A 1, Lambrou GI 2, Mourmouras N 3, Delakas D 3, Deltas C.
吳 華 席 Hua-Hsi Wu, MD OB/GYN, VGH-TPE Aug 12, 2008

吳 華 席 Hua-Hsi Wu, MD OB/GYN, VGH-TPE Aug 12, 2008
Figure S1 Enod11 Mtc27 MtGshs cDNA gDNA S. meliloti DPI --++ - + + - Supporting Information Fig. S1. Validation of the selected biological conditions for.

Figure S1 Enod11 Mtc27 MtGshs cDNA gDNA S. meliloti DPI Supporting Information Fig. S1. Validation of the selected biological conditions for.
Rate of breast cancer-specific survival Months Low gene expression (N=252) High gene expression (N=37) P < 0.0001(Log-rank) a Months Low gene expression.

Rate of breast cancer-specific survival Months Low gene expression (N=252) High gene expression (N=37) P < (Log-rank) a Months Low gene expression.
0 1000 2000 3000 4000 5000 020406080100120 ADT, Estramustine, Dexamethasone Prednisolone Radiotherapy (Months) (ng/mL) PSA Time Patient A Patient B Patient.

ADT, Estramustine, Dexamethasone Prednisolone Radiotherapy (Months) (ng/mL) PSA Time Patient A Patient B Patient.
Disease B A C SUPPLEMENTARY FIGURE 1 Molecular Function D.

Disease B A C SUPPLEMENTARY FIGURE 1 Molecular Function D.
Example of a DNA array used to study gene expression (note green, yellow red colors; also note.

Example of a DNA array used to study gene expression (note green, yellow red colors; also note.
Normal skin tissue Supplementary Fig 1A KLF4 has a tumor suppressive function in human skin cancer. Skin cancer tissues were deparaffinized and IHC was.

Normal skin tissue Supplementary Fig 1A KLF4 has a tumor suppressive function in human skin cancer. Skin cancer tissues were deparaffinized and IHC was.
Date of download: 5/30/2016 Copyright © 2016 American Society of Anesthesiologists. All rights reserved. Fig. 4. Effects of human placental multipotent.

Date of download: 5/30/2016 Copyright © 2016 American Society of Anesthesiologists. All rights reserved. Fig. 4. Effects of human placental multipotent.
Condition MiaPaCa-2 Control Gem (100nm) AZD1775 (200nM) Gem + AZD1775 Panc-1 Control Gem (50nm) AZD1775 (200nM) Gem + AZD1775 Capan-1 Control Gem (50nm)

Condition MiaPaCa-2 Control Gem (100nm) AZD1775 (200nM) Gem + AZD1775 Panc-1 Control Gem (50nm) AZD1775 (200nM) Gem + AZD1775 Capan-1 Control Gem (50nm)
1st workshop of the Aberdeen Microarray Analysis Network (AMAN)

1st workshop of the Aberdeen Microarray Analysis Network (AMAN)
Figure S1 A B Additional file 1 : Figure S1

Figure S1 A B Additional file 1 : Figure S1

Similar presentations

Ads by Google